ストックスクリーナーアプリを入手
65.72
1.69%
-1.13
プレマーケット:
66.08
0.36
+0.55%
前日終値:
$66.85
開ける：
$66.7
24時間の取引高:
1.74M
Relative Volume:
0.50
時価総額：
$14.52B
収益：
$4.03B
当期純損益:
$556.70M
株価収益率:
27.73
EPS:
2.37
ネットキャッシュフロー:
$970.10M
1週間 パフォーマンス:
+1.45%
1か月 パフォーマンス:
+1.77%
6か月 パフォーマンス:
-8.34%
1年 パフォーマンス:
-14.08%
1日の値動き範囲:
$65.62
$66.92
1週間の範囲:
$64.05
$67.06
52週間の値動き範囲:
$51.90
$84.67
Hologic Inc Stock (HOLX) Company Profile
HOLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
65.72 | 14.52B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
512.06 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
175.97 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.48 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
254.40 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
227.18 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-27 | 繰り返されました | Needham | Hold |
| 2025-03-03 | ダウングレード | Argus | Buy → Hold |
| 2025-02-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-02-03 | ダウングレード | Needham | Buy → Hold |
| 2024-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2024-12-10 | 開始されました | Jefferies | Hold |
| 2024-12-10 | 繰り返されました | Needham | Buy |
| 2024-10-01 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-06-27 | 開始されました | Stephens | Overweight |
| 2024-04-03 | アップグレード | Citigroup | Neutral → Buy |
| 2023-07-14 | アップグレード | Needham | Hold → Buy |
| 2022-12-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2022-10-13 | 開始されました | Mizuho | Buy |
| 2022-07-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-07-20 | 開始されました | UBS | Neutral |
| 2022-07-18 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-12-15 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | Redburn | Neutral |
| 2021-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-11-20 | ダウングレード | Needham | Buy → Hold |
| 2020-11-05 | 繰り返されました | Needham | Buy |
| 2020-06-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-06-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-04-30 | 繰り返されました | Needham | Buy |
| 2020-04-30 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-04-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-03-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-01-13 | 繰り返されました | Needham | Buy |
| 2020-01-08 | 開始されました | Wells Fargo | Equal Weight |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-09-26 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-08-01 | 繰り返されました | Needham | Buy |
| 2019-05-02 | 繰り返されました | Needham | Buy |
| 2019-01-31 | 繰り返されました | Needham | Buy |
| 2019-01-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-09 | 開始されました | UBS | Neutral |
| 2018-09-13 | ダウングレード | BofA/Merrill | Buy → Neutral |
すべてを表示
Hologic Inc (HOLX) 最新ニュース
Hips & Knees Reconstructive Market Attracts 3D Implant - openPR.com
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead? - The Globe and Mail
Hologic (HOLX) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Citi upgrades Hologic stock rating to Buy on valuation and growth outlook By Investing.com - Investing.com South Africa
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap? - Yahoo Finance
The Price Is Right For Hologic, Inc. (NASDAQ:HOLX) - 富途牛牛
BioZorb Lawsuit LawyerBreast Biopsy Marker RecallJuly 2025 Update - Levin Papantonio
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know - MSN
BioZorb Lawsuit and Settlement Information: July 2025 - AboutLawsuits.com
Hologic to Announce Financial Results for the Third Quarter of F - GuruFocus
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025 - Business Wire
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern - The Globe and Mail
Hologic, Inc.(NasdaqGS: HOLX) dropped from Russell 1000 Dynamic Index - MarketScreener
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value - Zacks Investment Research
Is Hologic, Inc. (NASDAQ:HOLX) Undervalued Despite Strong Growth Prospects? - AInvest
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
How Is Hologic’s Stock Performance Compared To Other Health Care Equipment Stocks? - Barchart.com
Hologic Joins NEST Governance Committee - Medical Product Outsourcing
From Now to 2032: Unpacking the Bone Mineral Densitometry - openPR.com
Global C-Arms Market Trends & Forecast 2025-2032 | Major - openPR.com
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Breast Cancer Diagnostics Market OutlookImaging, Biopsy & - openPR.com
Chennai Open added to 2025 Hologic WTA Tour calendar - WTA Tennis
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence? - Yahoo Finance
Is Hologic (NASDAQ:HOLX) Using Too Much Debt? - simplywall.st
Bone Mineral Testing Market Generated Opportunities, Future - openPR.com
Tomosynthesis Market Set to Witness High Growth with Adoption of 3D Breast Imaging | Hologic Inc., GE Healthcare - openPR.com
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate? - The Globe and Mail
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact? - MSN
Can Hologic Lean On Its Strengths In A Tough Macroeconomic Climate? - Barchart.com
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know - Yahoo Finance
CGH and Hologic ink MoU on breast imaging research and education - MSN
Hologic Climbs 13% In A Month: How Should You Play The Stock? - Barchart.com
Hologic Climbs 13% in a Month: How Should You Play the Stock? - The Globe and Mail
Breast Cancer Diagnostic Market Set to Witness Advances in Imaging and Biomarkers | Hologic, GE Healthcare - openPR.com
Parallel Advisors LLC Has $60,000 Position in Hologic, Inc. (NASDAQ:HOLX) - Defense World
Uterine Fibroid Treatment Devices Market Set to Witness - openPR.com
Histology And Cytology Market Is Booming So Rapidly 2025-2032 - openPR.com
BNP Paribas Exane Adjusts Price Target on Hologic to $73 From $71, Maintains Outperform Rating - MarketScreener
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
Hologic at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com
Hologic at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK
Transcript : Hologic, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11 - MarketScreener
Gynecological Devices Market Set to Witness Significant Growth - openPR.com
Hologic at 45th Annual William Blair Growth Stock Conference: Strategic Focus on Women’s Health By Investing.com - Investing.com South Africa
Hologic at 45th Annual William Blair Growth Stock Conference: Strategic Focus on Women’s Health - Investing.com Australia
Hologic, Inc. (NASDAQ:HOLX) Short Interest Up 35.7% in May - Defense World
Hologic turns down $16 billion buyout offer from TPG and Blackstone - DOTmed
Breast Lesion Localization Methods Market Set to Witness Demand - openPR.com
Bone Densitometers Market Generated Opportunities, Future - openPR.com
Hologic Inc (HOLX) 財務データ
収益
当期純利益
現金流量
EPS
Hologic Inc (HOLX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Option Exercise |
62.60 |
22,902 |
1,433,659 |
52,813 |
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Sale |
76.34 |
24,856 |
1,897,482 |
27,957 |
2.52%
大文字化:
|
ボリューム (24 時間):